To Evaluate Safety and Effectiveness of RovatitanTab.

LG Chem1,000 enrolled

Overview

To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia

* Effectiveness: the ratio of patients who reach target BP or LDL-cholesterol * Safety: we will collect safety data

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Hypertension Hyperlipidemias

Interventions

Rosuvastatin/ValsartanDRUG

Rovatitan QD for 12 weeks

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who have hypertension and hyperlipidemia and older than 19 years * Patients who undertstand purpose and method of study, agree with study Exclusion Criteria: * Patients who have been administered Rosuvastatin/Valsartan as a anti- hyperlipiddemic/anti-hypertensive drugs * Uncontrolled hypertension (SBP\>=180mmHg or DBP\>=110mmHg) * Patients who participated another clinical study or observational study 3 months ago.

Outcomes

Primary Outcomes

The ratio of patients who reach the target BP

SBP/DBP\<140/90mmHg (\<60years), SBP/DBP\<150/90mmHg (\>=60years)

Time frame: 12weeks

The ratio of patients who reach the target LDLcholesterol

target LDL refered to Hyperlipidemia pharmacotherapy

Time frame: 12weeks

Secondary Outcomes

The ratio of patients who reach the target BP and LDL-c

SBP/DBP\<140/90mmHg (\<60years), SBP/DBP\<150/90mmHg (\>=60years), target LDL

Time frame: 12weeks

Central Contacts

songyi Park

CONTACT

=82-2-6987-4195 songyi-park@lgchem.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.